Combination therapy for newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of two chemotherapy drugs (idarubicin and cytarabine) plus a newer targeted medication (venetoclax) for people with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The goal is to see if this treatment is effective and safe as an initial therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 60 years old.
- You must have newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS), and have not yet received treatment for it.
- You should be generally active and able to carry out daily tasks, but it’s okay if you need some rest.
- You must have adequate liver, kidney, and heart function, as confirmed by tests.
- You must not have had prior treatment with a type of chemotherapy called anthracycline (like doxorubicin).
- You must not have an active infection (HIV, hepatitis B or C), severe heart condition, or respiratory disease requiring continuous oxygen.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines three standard chemotherapy drugs (fludarabine, cytarabine, idarubicin) with a targeted therapy (venetoclax) to treat acute myeloid leukemia (AML) and a related condition called MDS with high blast counts. The goal is to see if adding venetoclax improves results.
This trial tests a combination of three drugs—daunorubicin, cytarabine, and venetoclax—for people with newly diagnosed AML who are strong enough to receive intensive chemotherapy. The goal is to see if adding venetoclax helps improve treatment outcomes.
This trial is testing new drug combinations for people with newly diagnosed, high-risk AML who have not yet started treatment. It aims to find more effective therapies for this aggressive form of leukemia.
This trial combines three drugs to treat certain types of leukemia or a related blood condition. It may be an option for people who cannot have standard intensive chemo, or for those whose disease has come back.
This trial tests a combination of three drugs (hydroxychloroquine, decitabine, and venetoclax) for people with acute myeloid leukemia (AML) that is either hard to treat or very high-risk. The goal is to see if this combination can help control the leukemia and what side effects it may cause.
This trial tests a three-drug combination (venetoclax, chidamide, and azacitidine) followed by another combination (decitabine plus MAG) for older adults with untreated acute myeloid leukemia (AML) who cannot have standard chemotherapy. It aims to offer a gentler but effective treatment option.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.